Heterogeneity of response to biologic treatment: perspective for psoriasis
- PMID: 23921949
- DOI: 10.1038/jid.2013.326
Heterogeneity of response to biologic treatment: perspective for psoriasis
Abstract
Psoriasis treatment responses are affected by patient characteristics. However, the literature does not contain reviews of factors that affect the response to biologic therapies. We therefore performed a comprehensive literature search to identify papers describing demographic, lifestyle, and clinical factors associated with response to biologic drug therapy in psoriatic patients. We found that age, gender, ethnicity, alcohol consumption, smoking, geographic location, age at diagnosis, duration and severity of psoriasis, and baseline C-reactive protein levels did not consistently affect response to biologic psoriasis therapy. However, increased body mass index (BMI) appears to adversely affect responses. It might therefore be valuable to include BMI as a stratification variable in future studies of psoriasis therapies and to consider a patient's weight or BMI when selecting a systemic psoriasis treatment.
Similar articles
-
Biologic therapy in psoriasis: perspectives on associated risks and patient management.J Cutan Med Surg. 2012 May-Jun;16(3):153-68. doi: 10.1177/120347541201600305. J Cutan Med Surg. 2012. PMID: 22713438 Review.
-
Biologic agents in the treatment of psoriasis.Recent Pat Inflamm Allergy Drug Discov. 2007 Nov;1(3):193-217. doi: 10.2174/187221307782418919. Recent Pat Inflamm Allergy Drug Discov. 2007. PMID: 19075983 Review.
-
An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.Clin Ther. 2003 Oct;25(10):2487-505. doi: 10.1016/s0149-2918(03)80313-2. Clin Ther. 2003. PMID: 14667953 Review.
-
Combining traditional agents and biologics for the treatment of psoriasis.Semin Cutan Med Surg. 2005 Mar;24(1):37-45. doi: 10.1016/j.sder.2005.01.002. Semin Cutan Med Surg. 2005. PMID: 15900797 Review.
-
Newer treatment options for patients with moderate-to-severe psoriatic disease.Nurse Pract. 2006 Aug;31(8):5-6,11. doi: 10.1097/00006205-200608000-00002. Nurse Pract. 2006. PMID: 16966969 Review. No abstract available.
Cited by
-
Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice.J Clin Med. 2022 May 26;11(11):3011. doi: 10.3390/jcm11113011. J Clin Med. 2022. PMID: 35683398 Free PMC article.
-
Psoriasis Patients with Specific HLA-Cw Alleles and Lower Plasma IL-17 Level Show Improved Response to Topical Lindioil Treatment.Pharmgenomics Pers Med. 2022 May 13;15:515-524. doi: 10.2147/PGPM.S351452. eCollection 2022. Pharmgenomics Pers Med. 2022. PMID: 35592551 Free PMC article.
-
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).J Invest Dermatol. 2015 Nov;135(11):2632-2640. doi: 10.1038/jid.2015.208. Epub 2015 Jun 8. J Invest Dermatol. 2015. PMID: 26053050
-
Retrospective pharmacogenetic study of psoriasis highlights the role of KLK7 in tumour necrosis factor signalling.Br J Dermatol. 2023 Dec 20;190(1):70-79. doi: 10.1093/bjd/ljad332. Br J Dermatol. 2023. PMID: 37672660 Free PMC article.
-
Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility.Nat Commun. 2015 Apr 23;6:6916. doi: 10.1038/ncomms7916. Nat Commun. 2015. PMID: 25903422 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials